/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

DexCom, Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$64.5213 0.0062(0.62%) DXCM at 04 Dec 2025 04:30 PM Medical Devices
Lowest Today 64.24
Highest Today 65.16
Today’s Open 64.46
Prev. Close 64.45
52 Week High 93.25
52 Week Low 54.11
Day’s Range: Low 64.24 High 65.16
52-Week Range: Low 54.11 High 93.25
1 day return -
1 Week return +2.22
1 month return +6.04
3 month return -19.69
6 month return -24.23
1 year return -19.96
3 year return -44.35
5 year return -25.5
10 year return -

Institutional Holdings

Vanguard Group Inc 12.32

BlackRock Inc 9.95

State Street Corp 4.30

Baillie Gifford & Co Limited. 4.26

Vanguard Total Stock Mkt Idx Inv 3.14

Jennison Associates LLC 2.94

Geode Capital Management, LLC 2.75

Sands Capital Management, LLC 2.54

Vanguard 500 Index Investor 2.47

UBS Asset Mgmt Americas Inc 2.33

Vanguard Mid Cap Index Institutional 2.23

Invesco QQQ Trust 2.06

Nuveen, LLC 1.93

Massachusetts Financial Services Company 1.68

JPMorgan Chase & Co 1.57

Morgan Stanley - Brokerage Accounts 1.43

Capital Research Global Investors 1.38

NORGES BANK 1.32

Fidelity 500 Index 1.27

Amvescap Plc. 1.27

SPDR® S&P 500® ETF 1.21

iShares Core S&P 500 ETF 1.20

Vanguard Growth Index Investor 1.16

Sands Capital Global Growth Equity 1.13

Amundi 1.11

Groupama Asset Management 1.02

American Century Companies Inc 0.99

Bank of New York Mellon Corp 0.99

Northern Trust Corp 0.98

CREF Growth R3 0.90

Vanguard Mid-Cap Growth ETF 0.84

BlackRock Mid-Cap Growth Equity Instl 0.77

Sands Capital Select Growth TE Inst EQ 0.77

MFS Mid Cap Growth Equity 0.70

The Health Care Select Sector SPDR® ETF 0.68

Harbor Capital Appreciation Instl 0.68

MFS Mid Cap Growth A 0.68

iShares Russell Mid-Cap Growth ETF 0.66

Vanguard Institutional Index I 0.60

State St S&P 500® Indx SL Cl III 0.53

Market Status

Strong Buy: 17

Buy: 6

Hold: 3

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 25274.40 M

PB Ratio 9.0876

PE Ratio 35.8056

Enterprise Value 24027.33 M

Total Assets 6484.50 M

Volume 3710786

Company Financials

Annual Revenue FY24:4033000000 4033.0M, FY23:3403000000 3403.0M, FY22:2909800000 2909.8M, FY21:2448500000 2448.5M, FY20:1926700000 1926.7M

Annual Profit FY24:2465700000 2465.7M, FY23:2173600000 2173.6M, FY22:1883100000 1883.1M, FY21:1680500000 1680.5M, FY20:1280100000 1280.1M

Annual Net worth FY24:576200000 576.2M, FY23:377000000 377.0M, FY22:341200000 341.2M, FY21:154700000 154.7M, FY20:493600000 493.6M

Quarterly Revenue Q3/2025:1209300000 1209.3M, Q2/2025:1157100000 1157.1M, Q1/2025:1036000000 1036.0M, Q4/2024:1113500000 1113.5M, Q3/2024:994200000 994.2M

Quarterly Profit Q3/2025:731400000 731.4M, Q2/2025:688800000 688.8M, Q1/2025:589000000 589.0M, Q4/2024:654000000 654.0M, Q3/2024:593800000 593.8M

Quarterly Net worth Q3/2025:283800000 283.8M, Q2/2025:179800000 179.8M, Q1/2025:105400000 105.4M, Q4/2024:151700000 151.7M, Q3/2024:134600000 134.6M

Fund house & investment objective

Company Information DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Organisation Medical Devices

Employees 10200

Industry Medical Devices

CEO Mr. Kevin Ronald Sayer

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow